{
    "clinical_study": {
        "@rank": "164655", 
        "arm_group": [
            {
                "arm_group_label": "U100", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "U200", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Africa. The aim of this trial is to determine if a new\n      formulation (U200) of insulin aspart containing 200 U/mL is bioequivalent to that of a\n      marketed insulin aspart formulation (U100)."
        }, 
        "brief_title": "Comparison of Two Insulin Aspart Formulations in Healthy Volunteers", 
        "completion_date": {
            "#text": "October 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Healthy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Normal findings in medical history and physical examination unless the investigator\n             considers any abnormality to be clinically irrelevant\n\n          -  Normal laboratory values, electrocardiogram (ECG), and vital signs unless the\n             investigator considers any abnormality to be clinically irrelevant\n\n          -  Body mass index (BMI) 18-26 kg/m^2 (both inclusive)\n\n          -  Weight 60-90 kg\n\n          -  Non-smoker\n\n        Exclusion Criteria:\n\n          -  Any condition requiring the regular use of any medication\n\n          -  Known or suspected allergy to the trial product or related products\n\n          -  Family history of type 1 diabetes mellitus"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698697", 
            "org_study_id": "NN248-1494"
        }, 
        "intervention": {
            "arm_group_label": [
                "U100", 
                "U200"
            ], 
            "description": "Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour  infusion", 
            "intervention_name": "insulin aspart", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 2, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bloemfontein", 
                    "country": "South Africa", 
                    "zip": "9324"
                }
            }
        }, 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Centre, Randomized, Balanced Double-blind, Cross-Over Trial Investigating the Bioequivalence of a Continuous Subcutaneous Infusion of a Marketed NovoRapid Formulation Containing 100 U/ml and a New NovoRapid Formulation Containing 200 U/ml in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Birgitte Bentz Damholt, Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Africa: Medicines Control Council", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the curve (AUC)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Area under the glucose infusion rate curve", 
                "safety_issue": "No"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698697"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax (maximum plasma concentration)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Time to reach maximum (tmax)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Terminal half-life (t\u00bd)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Incidence of hypoglycemic events", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "No"
            }, 
            {
                "measure": "GIRmax: The maximal GIR (glucose infusion rate)", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}